Healive (Hepatitis A vaccine inactivated) / Sinovac - LARVOL DELTA

Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old (clinicaltrials.gov) - P4 | N=1092 | Active, not recruiting | Sponsor: Sinovac Biotech Co., Ltd | Trial primary completion date: Mar 2024 ➔ Mar 2028

Trial primary completion date • Hepatology • Infectious Disease • Inflammation

Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old (clinicaltrials.gov) - P4 | N=1092 | Active, not recruiting | Sponsor: Sinovac Biotech Co., Ltd | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Oct 2023 ➔ Mar 2024

Enrollment closed • Trial primary completion date • Hepatology • Infectious Disease • Inflammation

Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old (clinicaltrials.gov) - P4 | N=1000 | Not yet recruiting | Sponsor: Sinovac Biotech Co., Ltd

New P4 trial • Hepatology • Infectious Disease • Inflammation

Immunogenicity persistence of hepatitis A vaccines Healive® and Havrix® among children:15 years follow-up and long-term prediction. (PubMed, Hum Vaccin Immunother) - "Compared to Havrix®, the vaccine Healive® showed a stronger protective effect and better persistence among children at 15 years post-full immunization. Prediction indicated at least 30 years of antibody persistence for Healive® and at least 25 years for Havrix®."

Journal • Hepatology • Infectious Disease • Inflammation

Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance. (PubMed, Vaccine) - "Concomitant administration of inactivated hepatitis A vaccine (Healive®) with other vaccines has a similar safe profile as Healive® alone."

Journal • P4 data • Hepatology • Infectious Disease • Inflammation